Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

BACKGROUND: Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. This study...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Health Qual Life Outcomes
Autori principali: Reynolds, Shannon L., Ghate, Sameer R., Sheer, Richard, Gandhi, Pranav K., Moretz, Chad, Wang, Cheng, Sander, Stephen, Costantino, Mary E., Annavarapu, Srinivas, Andrews, George
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5480105/
https://ncbi.nlm.nih.gov/pubmed/28637460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12955-017-0705-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi